Riverwater Partners, an investment management company, released its “Micro Opportunities Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. The strategy reported solid absolute returns in the quarter but lagged the benchmark as it did not keep pace with the strong rally. The strategy continues to focus on quality companies in the volatile environment. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025. In its third-quarter 2025 investor ...

Core Viewpoint - ReNew Energy Global Plc (NASDAQ:RNW) experienced a significant decline of 27.15% in its stock price, closing at $5.50, following the withdrawal of Masdar from a $1 billion acquisition plan [1][3]. Group 1: Acquisition Details - Masdar officially withdrew from a consortium aimed at taking ReNew Energy Global Plc private [2]. - The acquisition proposal was initially set at $7.07 per share and was raised to $8.15 per share after a year of negotiations [3]. - The consortium included CPP Investments, ADIA (through Platinum Hawk), and ReNew's founder and CEO, Sumant Sinha [3]. Group 2: Market Reaction - The withdrawal of Masdar led to a complete halt of the merger proposal, resulting in a sharp sell-off of ReNew Energy's shares [3]. - The market response indicates a loss of investor confidence in ReNew Energy following the failed acquisition attempt [1][3]. Group 3: Future Outlook - ReNew Energy Global Plc has not yet announced its next steps following the withdrawal of the acquisition transaction [4].

Core Insights - Riverwater Partners' Small Cap Strategy reported solid results for Q3 2025 but lagged behind the benchmark due to the market's preference for lower-quality companies [1] - The strategy focuses on higher-quality companies with strong fundamentals and a clear path to profitability, positioning itself well in a challenging market [1] Company Performance - Haemonetics Corporation (NYSE:HAE) had a one-month return of 8.06% but experienced a 2.03% decline over the last 52 weeks, closing at $80.40 per share with a market capitalization of $3.873 billion [2] - The company faced challenges due to softer-than-expected demand in certain product lines, leading to a decision to exit the position in Q3 2025 to redeploy capital into opportunities with clearer near-term catalysts [3] Revenue and Market Position - In Q2 of fiscal 2026, Haemonetics reported revenue of $327 million, reflecting a 5% decline [4] - Despite its potential, Haemonetics is not among the most popular stocks among hedge funds, with 36 hedge fund portfolios holding its shares at the end of Q3, up from 29 in the previous quarter [4]

Core Insights - Riverwater Partners' Small Cap Strategy reported solid results for Q3 2025 but lagged behind the benchmark due to the market's preference for lower-quality companies [1] - The strategy focuses on higher-quality companies with strong fundamentals and a clear path to profitability, positioning itself well for challenging market conditions [1] - Vestis Corporation (NYSE:VSTS) was highlighted as a stock of interest, showing a one-month return of 38.46% but a significant 53.07% decline over the past 52 weeks [2] Company Analysis - Vestis Corporation is undergoing a business turnaround, which is expected to take longer than initially anticipated, compounded by a debt overhang that may hinder reinvestment [3] - The company is not among the 30 most popular stocks among hedge funds, with 27 hedge fund portfolios holding its shares at the end of Q3 2025, down from 34 in the previous quarter [4] - While Vestis Corporation has potential, the company is viewed as less favorable compared to certain AI stocks that are believed to offer greater upside potential and lower downside risk [4]

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. The Small Cap Core Strategy reported solid results for the quarter but did not keep pace with the sharp rally, thus lagging the benchmark. The market’s preference for lower-quality companies persisted in the quarter and contributed significantly to the benchmark’s outperformance. On the other hand, the strategy remains focused on higher-quality compa ...

The share price of Enerflex Ltd. (NYSE:EFXT) surged by 9.22% between December 5 and December 12, 2025, putting it among the Energy Stocks that Gained the Most This Week. Here is Why Enerflex (EFXT) Gained This Week Enerflex Ltd. (NYSE:EFXT) offers energy infrastructure and energy transition solutions in North America, Latin America, and the Eastern Hemisphere. On December 9, Raymond James upgraded Enerflex Ltd. (NYSE:EFXT) from ‘Outperform’ to ‘Strong Buy’, while also raising its price target from C$24. ...

Hormel Foods Corporation (NYSE:HRL) is included among the 13 Best Blue Chip Stocks to Buy Under $50. Hormel (HRL) Featured in Barclays’ Forward Look at Agriculture and Protein Demand On December 9, Barclays cut its price target on Hormel Foods Corporation (NYSE:HRL) to $31 from $30 as it outlined its view for the Americas agribusiness sector. However, the firm maintained an Overweight rating on the shares. Barclays expects the agriculture market to deliver mixed results next year. The firm is more optimi ...

Wasatch Global Investors, an asset management company, released its third-quarter 2025 “Wasatch Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. US small-cap equities rallied strongly in the third quarter. The Fed Reserve’s interest rate cut supported the rally. However, the fund-Investor Class struggled to keep up with the rally and ended the period down -3.17% vs. 12.19% gain for the Russell 2000 Growth Index. In addition, please check the fund’s top five holdings t ...

Core Insights - TimesSquare Capital Management's "U.S. Focus Growth Strategy" reported a gross return of 4.00% and a net return of 3.78% for Q3 2025, outperforming the Russell Midcap Growth Index's return of 2.78% [1] - EMCOR Group, Inc. (NYSE:EME) was highlighted as a key stock, with a one-month return of 2.00% and a 52-week gain of 28.71%, closing at $623.65 per share with a market capitalization of $27.918 billion [2][3] Company Performance - EMCOR Group, Inc. reported consolidated revenues of $4.3 billion in Q3 2025, marking a 16.4% increase from Q3 2024 [4] - The company's strong performance was driven by significant growth in its US Electrical segment, particularly due to data center expansion, which contributed to a 21% stock increase [3] Investment Positioning - EMCOR Group is well-positioned to capture a significant share of large data center and manufacturing projects, supported by its scale and advanced capabilities in virtual design and construction [3] - Despite its potential, EMCOR is not among the top 30 most popular stocks among hedge funds, with 58 hedge fund portfolios holding its stock at the end of Q3 2025, up from 51 in the previous quarter [4]

Core Insights - TimesSquare Capital Management's "U.S. Focus Growth Strategy" reported a gross return of 4.00% and a net return of 3.78% for Q3 2025, outperforming the Russell Midcap Growth Index's return of 2.78% [1] - Cintas Corporation (NASDAQ:CTAS) is highlighted as a key stock, with a one-month return of 2.05% and a 52-week loss of 11.46%, closing at $187.53 per share with a market capitalization of $75.565 billion [2][4] Company Performance - Cintas Corporation reported better-than-expected fiscal first-quarter results, but its stock experienced an 8% pullback due to concerns regarding employment, industry pricing, and cost pressures [3] - In Q1 of fiscal 2026, Cintas Corporation's total revenue grew by 8.7% to $2.72 billion [4] Hedge Fund Interest - Cintas Corporation was held by 61 hedge fund portfolios at the end of Q3 2025, an increase from 57 in the previous quarter, indicating growing interest among institutional investors [4]